Future research should focus on elucidating the molecular mechanisms involved—particularly the PI3K/AKT/mTOR and p53-mediated apoptotic pathways—and evaluating the efficacy and safety of this combination in in vivo breast cancer models to better understand its clinical relevance. The gene discussed is AKT1; the disease is breast carcinoma.